Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics (Nasdaq: PVLA) will host a live webcast conference call on February 24, 2026 at 8:00am ET to discuss topline results from the Phase 3 SELVA trial of QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.
The company plans to release topline results at approximately 6:30am ET prior to the call. A replay will be available about 2 hours after the call and archived for 90 days in the Events & Presentations section of Palvella’s website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PVLA
+37.08%
19 alerts
+37.08%Session close to close
+56.6%Peak in 20 hr 42 min
$1.10BMarket Cap
0.8xRel. Volume
In the Feb 24 session, PVLA gained 37.08%, reflecting a significant positive market reaction.
Argus tracked a peak move of +56.6% during that session.
Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
The stock surged +37.1% in the session following this news. A strong positive reaction aligns with P...
Analysis
The stock surged +37.1% in the session following this news. A strong positive reaction aligns with PVLA’s history of sharp moves around clinical and regulatory milestones, where prior news produced swings from +11.72% to -9.74%. The Phase 3 SELVA topline discussion would represent a pivotal data readout for QTORIN rapamycin. Investors have also seen recent insider option exercises and sales, as disclosed in multiple Form 4 and Form 144 filings, which could temper enthusiasm if profit‑taking accelerates.
Key Figures
Phase:Phase 3QTORIN concentration:3.9%Conference time:8:00am ET+3 more
6 metrics
PhasePhase 3SELVA trial of QTORIN rapamycin
QTORIN concentration3.9%QTORIN rapamycin anhydrous gel formulation
Conference time8:00am ETConference call on February 24, 2026
Topline release time6:30am ETPlanned press release ahead of call
Webcast replay delay2 hoursApproximate time after call to replay availability
Replay archive period90 daysDuration webcast replay will be available
Positive Phase 2 TOIVA data in cutaneous venous malformations with FDA plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
PVLA has often reacted strongly to pipeline and clinical updates, with a mix of aligned and divergent moves versus generally positive news.
Recent Company History
Over the past few months, Palvella has built a narrative around its QTORIN™ platform and late-stage pipeline. On Dec 15, 2025, positive Phase 2 TOIVA topline data for QTORIN rapamycin in cutaneous venous malformations saw a -9.74% move despite favorable efficacy and safety. Fast Track designation for angiokeratomas on Dec 16, 2025 and subsequent leadership and scientific updates in early 2026 produced moves from +4.19% to +11.72%. Today’s announcement of an upcoming Phase 3 SELVA topline call fits this ongoing clinical‑progress narrative.
"to discuss topline results from the Phase 3 SELVA clinical trial assessing"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
qtorin™ 3.9% rapamycin anhydrous gelmedical
"SELVA clinical trial assessing the efficacy and safety of QTORIN™ 3.9% rapamycin anhydrous gel"
A topical prescription medicine formulated as a gel that contains 3.9% rapamycin anhydrous, a drug that acts on cellular growth and inflammation pathways. Investors watch this product because its safety and effectiveness, regulatory status, patent protection and patient demand determine potential sales and profit—think of it as a new consumer product entering a regulated market where approval, market size and pricing drive commercial value.
microcystic lymphatic malformationsmedical
"for the treatment of microcystic lymphatic malformations."
Microcystic lymphatic malformations are noncancerous clusters of very small, fluid-filled channels in the skin or deeper tissues that form when the lymphatic system develops abnormally; think of them as a sponge of tiny blisters under or on the skin. They matter to investors because they create specific medical needs—diagnostics, procedures, and drug or device treatments—that drive research, regulatory review, potential market size, reimbursement decisions, and liability risks for healthcare companies developing solutions.
clinical trialmedical
"Phase 3 SELVA clinical trial assessing the efficacy and safety"
A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.
webcasttechnical
"Webcast conference call to take place tomorrow, Tuesday, February 24, 2026"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET
WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a conference call and webcast tomorrow, Tuesday, February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial assessing the efficacy and safety of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations. The Company plans to issue a press release sharing the topline results at approximately 6:30am ET tomorrow, prior to the start of the call.
Conference Call
To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
When will Palvella (PVLA) release topline SELVA Phase 3 results?
Palvella will release topline SELVA results on February 24, 2026 at approximately 6:30am ET. According to the company, the press release will precede the 8:00am ET conference call to discuss those topline efficacy and safety findings.
What time is the Palvella (PVLA) conference call to discuss QTORIN SELVA results?
The Palvella conference call is scheduled for February 24, 2026 at 8:00am ET. According to the company, a live webcast with slides and a phone option will be available, followed by a replay archived on the website.
How can investors access the PVLA webcast and replay for the SELVA topline announcement?
Investors can access the live webcast via the Events & Presentations section of Palvella’s website or registration link for dial-in details. According to the company, a replay will be available about two hours after the call and archived for 90 days.
What is being discussed on Palvella's call about QTORIN 3.9% rapamycin gel (PVLA)?
The call will discuss topline efficacy and safety results from the Phase 3 SELVA trial in microcystic lymphatic malformations. According to the company, the presentation will include slides and management commentary about those topline findings.
Will Palvella (PVLA) provide slides or supplemental materials with the SELVA topline call?
Yes. The company said the live webcast will include slides accessible via its Events & Presentations webpage. According to Palvella, slide materials will accompany the webcast and replay for investor review.
